Literature DB >> 6129594

Antagonism of the apomorphine-induced yawning by "atypical" neuroleptics.

I Dubuc, P Protais, O Colboc, J Costentin.   

Abstract

In relatively small doses, the four "atypical" neuroleptics, sulpiride, clozapine, thoiridazine and mezilamine were effective antagonists of apomorphine-induced yawning in rats. Of the four drugs, used in doses which inhibited apomorphine-induced yawning almost completely, only clozapine also antagonized yawning induced by physostigmine. Therefore it appears that the antagonism of this effect of apomorphine, already reported for classical neuroleptic agents, is also shown by "atypical" ones. By combining apomorphine- and physostigmine-induced yawning, it is possible to assess the anticholinergic component in the antagonism of this effect of apomorphine and this may be of value for the understanding of the mechanisms underlying the "atypical" character.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6129594     DOI: 10.1016/0028-3908(82)90181-2

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  8 in total

1.  Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.

Authors:  Gregory T Collins; Jeffrey M Witkin; Amy H Newman; Kjell A Svensson; Peter Grundt; Jianjing Cao; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2005-04-15       Impact factor: 4.030

2.  Apomorphine-induced blinking and yawning in healthy volunteers.

Authors:  O Blin; G Masson; J P Azulay; J Fondarai; G Serratrice
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

3.  Interactions of drugs acting on central dopamine receptors and cholinoceptors on yawning responses in the rat induced by apomorphine, bromocriptine or physostigmine.

Authors:  M R Zarrindast; M Poursoltan
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

4.  5-HT1A receptor agonists prevent in rats the yawning and penile erections induced by direct dopamine agonists.

Authors:  P Simon; B Guardiola; J Bizot-Espiard; P Schiavi; J Costentin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

5.  Multifocal sites of action involved in dopaminergic-cholinergic neuronal interactions in yawning.

Authors:  I Ushijima; Y Mizuki; M Yamada
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

6.  Yawning is elicited by D2 dopamine agonists but is blocked by the D1 antagonist, SCH 23390.

Authors:  G Serra; M Collu; G L Gessa
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

7.  Involvement of septal and striatal dopamine D-2 receptors in yawning behavior in rats.

Authors:  K Yamada; M Tanaka; K Shibata; T Furukawa
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 8.  Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse.

Authors:  Carlos Roncero; Alfonso C Abad; Antonio Padilla-Mata; Elena Ros-Cucurull; Carmen Barral; Miquel Casas; Lara Grau-López
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.